CMN Markets February 2022 | CRISPR Stocks and...
Mar. 3, 2022
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Kyverna Therapeutics
Main focus: Next-generation cell therapies for autoimmune diseases
Company stage: Pre-clinical
Diseases (gene editing): Autoimmune diseases
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Emeryville, CA, USA
Website:https://kyvernatx.com/
Pipeline:https://kyvernatx.com/the-science/
Gene editing partnerships: Intellia Therapeutics
Kyverna Therapeutics develops cellular therapies to treat autoimmune and inflammatory diseases. This includes both engineered regulatory T cells, CAR-T and SynNotch CAR-T cells. The company has licensed Intellia Therapeutics' CRISPR-Cas9 technology for the development of its allogeneic CD19-targeting CAR-T cell therapy.
